Lithium for Hyperthyroidism

Direct Answer

Lithium is not a standard treatment for hyperthyroidism but can serve as a temporary bridge therapy in specific clinical scenarios when thionamides cannot be used and definitive treatment with radioactive iodine (RAI) is planned. 1

Clinical Role and Indications

Primary Use: Adjunct to Radioactive Iodine Therapy

Lithium increases intrathyroidal retention of radioactive iodine without reducing iodide uptake, thereby enhancing the radiation dose delivered to the thyroid gland. 2, 3
Meta-analysis of observational trials (N=851) demonstrated significant improvement in cure rates when lithium was added to RAI therapy (odds ratio 1.92,95% CI 1.24-2.96). 3
The success rate of RAI therapy improved from 73.3% with RAI alone to 90.0% when combined with lithium in patients with long-lasting Graves' hyperthyroidism. 4

Alternative Therapy When Thionamides Are Contraindicated

Lithium can be used as monotherapy to control hyperthyroidism when methimazole or propylthiouracil cannot be used due to adverse reactions (such as fulminant hepatitis) while awaiting definitive RAI treatment. 1
In one case report, a patient with methimazole-induced fulminant hepatitis achieved biochemical and clinical euthyroidism within 8 days using lithium 300 mg daily combined with high-dose hydrocortisone and propranolol. 1
Lithium levels even at subtherapeutic range (just below 0.4-0.6 mEq/L) may be sufficient to maintain euthyroid state. 1

Dosing and Administration

Standard Dosing Protocol

When used as adjunct to RAI: 900 mg lithium per day in three divided doses, starting 1 day before RAI administration and continuing for 5-7 days after therapy. 2, 4
Target serum lithium concentration: 0.4-0.6 mEq/L (mean achieved level approximately 0.571 ± 0.156 mmol/L). 2, 4
When used as monotherapy for hyperthyroidism: 300 mg daily, adjusted to maintain lithium levels just below therapeutic range (0.4-0.6 mEq/L). 1

Monitoring Requirements

Serum lithium levels must be measured on the fourth day after starting therapy and monitored regularly throughout treatment, as lithium toxicity is closely related to serum concentrations. 5, 2
Facilities for prompt and accurate serum lithium measurement must be available before initiating therapy. 5
Assess renal and liver function before starting lithium. 2
Regular monitoring of thyroid function tests (TSH, free T4, free T3) is required throughout lithium therapy to detect biochemical changes. 5

Duration of Therapy

Short-Term Use as RAI Adjunct

Treatment duration: 6-8 days total (1 day before RAI through 5-7 days after RAI administration). 2, 4
Antithyroid drugs should be withdrawn 7 days before RAI therapy. 4

Extended Use as Bridge Therapy

Lithium can be maintained for more than one month to control hyperthyroidism while awaiting elective radioablation, though this represents off-label extended use. 1
Trial removal of lithium results in reemergence of thyrotoxicosis within 24 hours, indicating the need for continuous therapy until definitive treatment. 1

Contraindications and Special Populations

Absolute Contraindications

Pregnancy and breastfeeding: Animal studies indicate potential fetal harm, and limited human data suggest possible fetal toxicity; lithium should be avoided unless absolutely necessary. 5
The risk-benefit balance differs significantly for pregnant or breastfeeding patients compared to the general population. 5

Relative Contraindications

Renal impairment: Lithium excretion relates principally to glomerular filtration rate and proximal tubule function. 6
Hyperthyroidism itself alters renal tubular function and may result in retention of lithium and systemic toxicity through induction of the proximal tubule sodium-hydrogen antiporter. 6

Adverse Effects and Safety Profile

Common Side Effects

The most frequently observed adverse effects are tremor, polyuria-polydipsia, diarrhea, and subclinical hypothyroidism. 7, 5
In the pilot study of 28 patients, only one patient experienced headache necessitating dose reduction, and one patient achieved a level of 1.5 mEq/L without obvious side effects. 2
Lithium-related side effects were infrequent and usually mild across multiple studies. 3

Serious Adverse Events

Lithium toxicity is closely related to serum lithium concentrations and can occur at doses close to therapeutic concentrations. 7, 5
No toxic effects were noticed during short-term (7-day) lithium treatment in the prospective study. 4
There were no reports of lithium toxicity in the open-label study among patients with Kleine-Levin syndrome. 7

Thyroid Storm Risk

One case report documented thyroid storm following dialysis to remove lithium in a patient with lithium toxicity and undiagnosed hyperthyroidism. 6
Lithium may mask signs of hyperthyroidism by inducing cellular unresponsiveness, potentially delaying diagnosis. 6

Clinical Benefits Beyond RAI Enhancement

Prevention of Post-RAI Thyrotoxicosis

Treatment with lithium for 7 days prevents transient worsening of hyperthyroidism after RAI therapy. 4
Serum levels of total T4 and free T4 increased while TSH decreased in the RAI-only group 7 days after treatment, but these changes did not occur in the lithium-treated group. 4

Faster Achievement of Hypothyroidism

Hypothyroidism was achieved faster in the lithium-treated group (1st month) compared to RAI alone (3rd month). 4
Euthyroidism slowly decreased in the lithium group, and not all patients became hypothyroid within 12 months, whereas euthyroidism rapidly declined in the RAI-only group with all cured patients becoming hypothyroid after 6 months. 4

Reduced Thyroid Hormone Levels

Lithium priming resulted in significantly reduced serum free T4 levels in patients with diffuse toxic goiter (Graves' disease). 2
Lithium priming also resulted in increased retention of radioiodine in other hyperthyroid subgroups, though differences were not statistically significant due to smaller sample sizes. 2

Evidence Quality and Limitations

Observational Evidence

The strongest evidence comes from retrospective cohort studies showing significant improvement in cure rates. 3
Interventional trials showed improvement in cure rates, but the difference did not reach statistical significance (OR 1.28,95% CI 0.85-1.91) due to the effect of a single large negative trial. 3

Study Populations

Most evidence pertains to Graves' disease (diffuse toxic goiter), with limited data on toxic multinodular goiter and autonomous functioning nodules. 2
The pilot study included only 28 patients across multiple hyperthyroid subgroups, limiting statistical power for subgroup analyses. 2

Practical Algorithm for Use

Step 1: Determine Indication

If thionamides are contraindicated or have caused serious adverse reactions (e.g., fulminant hepatitis) AND definitive RAI therapy is planned: Consider lithium as bridge therapy. 1
If RAI therapy is planned for long-lasting Graves' hyperthyroidism with prior treatment failure: Consider lithium as adjunct to enhance RAI efficacy. 4

Step 2: Pre-Treatment Assessment

Verify normal renal and liver function. 2
Measure morning cortisol and ACTH if central hypothyroidism or adrenal insufficiency is suspected (though this applies to thyroid hormone replacement, not lithium for hyperthyroidism). 8
Confirm facilities for prompt serum lithium measurement are available. 5
Exclude pregnancy and breastfeeding. 5

Step 3: Initiation and Monitoring

Start lithium 900 mg/day in three divided doses (or 300 mg daily for monotherapy). 2, 1
Measure serum lithium level on day 4 of therapy. 2
Target lithium level: 0.4-0.6 mEq/L. 1, 4
Monitor thyroid function tests regularly. 5

Step 4: RAI Administration (if applicable)

Administer RAI on day 5-7 of lithium therapy. 2, 4
Continue lithium for 5-7 days after RAI. 2, 4

Step 5: Follow-Up

Monitor for lithium toxicity symptoms (tremor, polyuria, diarrhea). 5
Assess thyroid function at 1,3,6, and 12 months post-RAI. 4
If using lithium as monotherapy, recognize that discontinuation results in rapid recurrence of thyrotoxicosis within 24 hours. 1

Critical Pitfalls to Avoid

Never initiate lithium without confirming availability of serum lithium measurement facilities, as toxicity can occur at near-therapeutic levels. 5
Do not use lithium in pregnant or breastfeeding women unless absolutely necessary, given documented fetal harm in animal studies. 5
Recognize that hyperthyroidism itself alters renal tubular function and may cause lithium retention and toxicity. 6
Be aware that lithium may mask clinical signs of hyperthyroidism through cellular unresponsiveness, potentially delaying recognition of thyroid storm. 6
Do not rely on lithium as definitive monotherapy for hyperthyroidism; it should only be used as a bridge to RAI or surgery. 1
Monitor for post-dialysis thyroid storm if lithium is removed rapidly in toxic patients with undiagnosed hyperthyroidism. 6

Can lithium be used to treat hyperthyroidism, and if so, what is the appropriate dose, duration, contraindications, and monitoring requirements?

Help us tailor your experience